Equity Overview
Price & Market Data
Price: $0.207
Daily Change: -$0.0026 / 1.26%
Range: $0.20 - $0.216
Market Cap: $5,383,200
Volume: 1,393,173
Performance Metrics
1 Week: -5.91%
1 Month: -71.32%
3 Months: -78.32%
6 Months: -80.29%
1 Year: -88.17%
YTD: -81.35%
Company Details
Employees: 30
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.